Back to Search
Start Over
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
- Source :
-
British journal of haematology [Br J Haematol] 2010 May; Vol. 149 (3), pp. 410-3. Date of Electronic Publication: 2010 Mar 10. - Publication Year :
- 2010
-
Abstract
- We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial. VT occurred in 59/1824 (3.2%) patients recruited over 5 years with 90% occurring during a period of Asparagine depletion. Pegylated Escherichia Coli Asparaginase (Peg-ASP) 1000 units/m(2) was used throughout. Thirty-four children received further Peg-ASP, most with concurrent heparin prophylaxis. There were no episodes of bleeding or recurrent thrombosis. Optimal Asparagine depletion is central to success of modern regimes for treatment of ALL. This report confirms a significant risk of thrombosis with such therapy, but demonstrates that re-exposure to Asparaginase is feasible and safe.
- Subjects :
- Adolescent
Anticoagulants therapeutic use
Antineoplastic Agents therapeutic use
Asparaginase therapeutic use
Child
Child, Preschool
Feasibility Studies
Female
Heparin, Low-Molecular-Weight therapeutic use
Humans
Infant
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Prospective Studies
Venous Thrombosis prevention & control
Antineoplastic Agents adverse effects
Asparaginase adverse effects
Venous Thrombosis chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2141
- Volume :
- 149
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 20201945
- Full Text :
- https://doi.org/10.1111/j.1365-2141.2010.08132.x